Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Moderate and severe haemophilia in Spain: An epidemiological update.

Aznar JA, Altisent C, Álvarez-Román MT, Bonanad S, Mingot-Castellano ME, López MF.

Haemophilia. 2018 May;24(3):e136-e139. doi: 10.1111/hae.13462. Epub 2018 Mar 26. No abstract available.

PMID:
29578308
2.

Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A.

García-Dasí M, Aznar JA, Jiménez-Yuste V, Altisent C, Bonanad S, Mingot E, Lucía F, Giménez F, López MF, Marco P, Pérez R, Fernández MÁ, Paloma MJ, Galmes B, Herrero S, García-Talavera JA.

Haemophilia. 2015 Jul;21(4):458-64. doi: 10.1111/hae.12618. Epub 2015 Feb 4.

PMID:
25649244
3.

Home-delivered ultrasound monitoring for home treatment of haemarthrosis in haemophilia A.

Aznar JA, Pérez-Alenda S, Jaca M, García-Dasí M, Vila C, Moret A, Querol F, Bonanad S.

Haemophilia. 2015 Mar;21(2):e147-50. doi: 10.1111/hae.12622. Epub 2015 Jan 27. No abstract available.

PMID:
25623041
4.

Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A.

Aznar JA, Moret A, Ibáñez F, Vila C, Cabrera N, Mesa E, Bonanad S.

Haemophilia. 2014 Sep;20(5):624-9. doi: 10.1111/hae.12439. Epub 2014 Apr 3.

PMID:
24697977
5.

Secondary prophylaxis vs. on-demand treatment to improve quality of life in severe adult haemophilia A patients: a prospective study in a single centre.

Aznar JA, García-Dasí M, Pérez-Alenda S, Marco A, Jaca M, Moret A, Querol F.

Vox Sang. 2014 Jan;106(1):68-74. doi: 10.1111/vox.12066. Epub 2013 Jun 27.

PMID:
23802855
6.

Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor-induced platelet agglutination method.

Cabrera N, Moret A, Caunedo P, Cid AR, Vila V, España F, Aznar JA.

Haemophilia. 2013 Nov;19(6):920-5. doi: 10.1111/hae.12203. Epub 2013 Jun 4.

PMID:
23730809
7.

Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.

Lissitchkov T, Matysiak M, Zavilska K, Laguna P, Gercheva L, Antonov A, Moret A, Caunedo P, Aznar JA, Woodward MK, Páez A.

Haemophilia. 2013 Sep;19(5):674-8. doi: 10.1111/hae.12148. Epub 2013 May 7.

PMID:
23647607
8.

Emerging viral infections‑-a potential threat for blood supply in the 21st century.

de Mendoza C, Altisent C, Aznar JA, Batlle J, Soriano V.

AIDS Rev. 2012 Oct-Dec;14(4):279-89. Review.

PMID:
23258302
9.

Assessment of the thrombin generation assay in haemophilia: comparative study between fresh and frozen platelet-rich plasma.

Vila V, Aznar JA, Moret A, Marco A, Navarro S, Vila C, España F.

Haemophilia. 2013 Mar;19(2):318-21. doi: 10.1111/hae.12044. Epub 2012 Nov 23.

PMID:
23174035
10.

Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.

Grancha S, Ortiz AM, Marañón C, Hampel K, Moret A, Zimmermann B, Jorquera JI, Aznar JA.

Haemophilia. 2012 Nov;18(6):982-9. doi: 10.1111/j.1365-2516.2012.02858.x. Epub 2012 May 30.

PMID:
22646163
11.

Is on-demand treatment effective in patients with severe haemophilia?

Aznar JA, Marco A, Jiménez-Yuste V, Fernández-Fontecha E, Pérez R, Soto I, Parra R, Moreno M, Mingot ME, Moret A; Spanish Haemophilia Epidemiological Study Working Group.

Haemophilia. 2012 Sep;18(5):738-42. doi: 10.1111/j.1365-2516.2012.02806.x. Epub 2012 Apr 27.

PMID:
22537601
12.

Liver transplantation in Spanish haemophiliacs.

Aznar JA, Marco A, Parra R, Jiménez-Yuste V, Lucía F, Balda I, Soto I.

Haemophilia. 2012 Jan;18(1):e15-6. doi: 10.1111/j.1365-2516.2011.02658.x. Epub 2011 Sep 28. No abstract available.

PMID:
21951767
13.

Joint protection in haemophilia.

Rodriguez-Merchan EC, Jimenez-Yuste V, Aznar JA, Hedner U, Knobe K, Lee CA, Ljung R, Querol F, Santagostino E, Valentino LA, Caffarini A.

Haemophilia. 2011 Sep;17 Suppl 2:1-23. doi: 10.1111/j.1365-2516.2011.02615.x. Review.

PMID:
21819491
14.

Ultrasonography in the monitoring of management of haemarthrosis.

Aznar JA, Abad-Franch L, Perez-Alenda S, Haya S, Cid AR, Querol F.

Haemophilia. 2011 Sep;17(5):826-8. doi: 10.1111/j.1365-2516.2011.02538.x. Epub 2011 Apr 19. No abstract available.

PMID:
21501338
15.

A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B.

Lissitchkov T, Matysiak M, Zavilska K, Laguna P, Gercheva L, Antonov A, Cabrera N, Aznar JA, Woodward MK, Páez A.

Haemophilia. 2011 Jul;17(4):590-6. doi: 10.1111/j.1365-2516.2010.02470.x. Epub 2011 Feb 7.

PMID:
21299747
16.

Focusing on haemophilia B: prophylaxis in Spanish patients.

Aznar JA, Lucia JF, Abad-Franch L, Rubio R, Jimenez-Yuste V, Perez R, Batlle J, Balda I, Muñoz-Robles J, Parra R; Spanish Haemophilia Epidemiological Study Working Group.

Haemophilia. 2011 May;17(3):542-3. doi: 10.1111/j.1365-2516.2010.02412.x. Epub 2010 Nov 11. No abstract available.

PMID:
21070494
17.

Prophylaxis therapy in haemophilia A: current situation in Spain.

Lucía JF, Aznar JA, Abad-Franch L, Escuin RR, Jiménez-Yuste V, Pérez R, Batlle J, Balda I, Alperovich G, Parra R; Spanish Haemophilia Epidemiological Study Working Group.

Haemophilia. 2011 Jan;17(1):75-80. doi: 10.1111/j.1365-2516.2010.02378.x. Epub 2010 Nov 11.

PMID:
21070481
18.

First application of MLPA method in severe von Willebrand disease. Confirmation of a new large VWF gene deletion and identification of heterozygous carriers.

Cabrera N, Casaña P, Cid AR, Moret A, Moreno M, Palomo A, Aznar JA.

Br J Haematol. 2011 Jan;152(2):240-2. doi: 10.1111/j.1365-2141.2010.08400.x. Epub 2010 Oct 19. No abstract available.

PMID:
20955405
19.

Implementation of SintromacWeb(R), a new internet-based tool for oral anticoagulation therapy telecontrol: Study on system consistency and patient satisfaction.

Ferrando F, Mira Y, Contreras MT, Aguado C, Aznar JA.

Thromb Haemost. 2010 May;103(5):1091-101. doi: 10.1160/TH09-07-0469. Epub 2010 Apr 13.

PMID:
20390224
20.

The national registry of haemophilia A and B in Spain: results from a census of patients.

Aznar JA, Abad-Franch L, Cortina VR, Marco P; INHERITED BLEEDING DISORDERS GROUP FROM THE SPANISH SOCIETY OF THROMBOSIS AND HAEMOSTASIS.

Haemophilia. 2009 Nov;15(6):1327-30. doi: 10.1111/j.1365-2516.2009.02101.x. Epub 2009 Sep 15. No abstract available.

PMID:
19754841
21.

Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.

Aznar JA, Cabrera N, Matysiak M, Zawilska K, Gercheva L, Antonov A, Montañés M, Páez AM, Lissitchkov T.

Haemophilia. 2009 Nov;15(6):1243-8. doi: 10.1111/j.1365-2516.2009.02052.x. Epub 2009 Jul 30.

PMID:
19659601
22.

Haemophilia in Spain.

Aznar JA, Lucía F, Abad-Franch L, Jiménez-Yuste V, Pérez R, Batlle J, Balda I, Parra R, Cortina VR.

Haemophilia. 2009 May;15(3):665-75. doi: 10.1111/j.1365-2516.2009.02001.x.

PMID:
19432921
23.

Identification of deletion carriers in hemophilia B: quantitative real-time polymerase chain reaction or multiple ligation probe amplification.

Casaña P, Haya S, Cid AR, Oltra S, Martínez F, Cabrera N, Aznar JA.

Transl Res. 2009 Mar;153(3):114-7. doi: 10.1016/j.trsl.2008.12.006. Epub 2009 Jan 27.

PMID:
19218093
24.
25.

Exercise and sport in the treatment of haemophilic patients: a systematic review.

Gomis M, Querol F, Gallach JE, González LM, Aznar JA.

Haemophilia. 2009 Jan;15(1):43-54. doi: 10.1111/j.1365-2516.2008.01867.x. Epub 2008 Aug 21. Review.

PMID:
18721151
26.

Novel missense mutation c.2685G>C (p.Q895H) in VWF gene associated with very low levels of VWF mRNA.

Cabrera N, Casaña P, Cid AR, Haya S, Moret A, Aznar JA.

Ann Hematol. 2009 Mar;88(3):245-7. doi: 10.1007/s00277-008-0576-7. Epub 2008 Aug 20.

PMID:
18712522
27.

Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain.

Batlle J, Villar A, Liras A, Alonso C, Altisent C, Brito D, Moreno M, Lucía F, Sedano C, Prieto M, Calvente N, Aznar JA, Jiménez V, Soriano V, Martorell JR, Iruín G, Bergua JM, Aguilar C.

Blood Coagul Fibrinolysis. 2008 Jul;19(5):333-40. doi: 10.1097/MBC.0b013e328300c814. Review.

PMID:
18600079
28.

One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype.

Cid AR, Calabuig M, Cortina V, Casaña P, Haya S, Moret A, Cabrera N, Aznar JA.

Haemophilia. 2008 Sep;14(5):1049-54. doi: 10.1111/j.1365-2516.2008.01781.x. Epub 2008 Jun 5.

PMID:
18540892
29.

Founder haplotype associated with the factor VIII Asp1241Glu polymorphism in a cohort of mild hemophilia A patients.

Casaña P, Martínez F, Cabrera N, Cid AR, Aznar JA.

J Thromb Haemost. 2008 Aug;6(8):1428-30. doi: 10.1111/j.1538-7836.2008.02983.x. Epub 2008 Apr 17. No abstract available.

30.

Severe and moderate hemophilia A: identification of 38 new genetic alterations.

Casaña P, Cabrera N, Cid AR, Haya S, Beneyto M, Espinós C, Cortina V, Dasí MA, Aznar JA.

Haematologica. 2008 Jul;93(7):1091-4. doi: 10.3324/haematol.12344. Epub 2008 Apr 9.

31.

Inhibitors in haemophilia A: current management and open issues.

Haya S, Moret A, Cid AR, Cortina V, Casaña P, Cabrera N, Aznar JA.

Haemophilia. 2007 Dec;13 Suppl 5:52-60. doi: 10.1111/j.1365-2516.2007.01574.x. Review.

PMID:
18078398
32.

Posturographic analysis of balance control in patients with haemophilic arthropathy.

Gallach JE, Querol F, González LM, Pardo A, Aznar JA.

Haemophilia. 2008 Mar;14(2):329-35. Epub 2007 Dec 10.

PMID:
18081832
33.

Treatment in a haemophiliac A patient with paroxysmal atrial fibrillation and ischemic heart disease.

Cid AR, Zorio E, Haya S, Zúñiga P, Rueda J, Casaña P, Cabrera N, Arnau MA, Aznar JA.

Haemophilia. 2007 Nov;13(6):760-2. No abstract available.

PMID:
17973853
34.

Inhibitor development in one patient and laboratory discrepancies in several families with both mild haemophilia and Arg531Cys mutation.

Cid AR, Casaña P, Cabrera N, Haya S, Cortina V, Aznar JA.

Haemophilia. 2007 Mar;13(2):206-8.

PMID:
17286776
35.
36.

Discrepant factor VIII activity in a family with mild haemophilia A and 531 mutation using various FVIII assays and APTT reagents.

Lucía JF, Aguilar C, Dobon M, Aznar JA, Tizano E, Borés C, Cornudella R, Calvo MT.

Haemophilia. 2005 Sep;11(5):561-4. No abstract available.

PMID:
16128904
37.

Effects of dynamic rotation on event-related brain potentials.

Núñez-Peña MI, Aznar JA, Linares D, Corral MJ, Escera C.

Brain Res Cogn Brain Res. 2005 Jul;24(2):307-16. Epub 2005 Mar 23.

PMID:
15993768
38.

Molecular analyses in hemophilia B families: identification of six new mutations in the factor IX gene.

Espinós C, Casaña P, Haya S, Cid AR, Aznar JA.

Haematologica. 2003 Feb;88(2):235-6. No abstract available.

39.

Orthoses in haemophilia.

Querol F, Aznar JA, Haya S, Cid A.

Haemophilia. 2002 May;8(3):407-12. Review.

PMID:
12010442
40.

Results of an orthopaedic survey in young patients with severe haemophilia in Spain.

Tusell JM, Aznar JA, Querol F, Quintana M, Moreno M, Gorina E; Orthopaedic Study Group.

Haemophilia. 2002 Mar;8 Suppl 2:38-42.

PMID:
11966852
41.

Significant linkage and non-linkage of type 1 von Willebrand disease to the von Willebrand factor gene.

Casaña P, Martínez F, Haya S, Espinós C, Aznar JA.

Br J Haematol. 2001 Dec;115(3):692-700.

PMID:
11736956
42.

Evaluation of an automated method for the quantification of von Willebrand factor antigen. Its application in the study of vascular dysfunction.

Villa P, Iborra J, Serra J, Gilsanz A, Casaña P, Aznar JA, Aznar J.

Haematologica. 2001 Nov;86(11):1180-5.

43.

Post-synoviorthesis rehabilitation in haemophilia.

Querol F, Rodriguez-Merchan EC, Aznar JA, Lopez-Cabarcos C, Villar A.

Haemophilia. 2001 Jul;7 Suppl 2:54-8.

PMID:
11564147
44.

Association of the 3467C>T mutation (T1156M) in the von Willebrand's factor gene with dominant type 1 von Willebrand's disease.

Casaña P, Martínez F, Haya S, Espinós C, Aznar JA.

Ann Hematol. 2001 Jul;80(7):381-3.

PMID:
11529461
45.

Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.

Gensana M, Altisent C, Aznar JA, Casaña P, Hernández F, Jorquera JI, Magallón M, Massot M, Puig L.

Haemophilia. 2001 Jul;7(4):369-74.

PMID:
11442641
46.

Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age.

Lorenzo JI, López A, Altisent C, Aznar JA.

Br J Haematol. 2001 Jun;113(3):600-3.

PMID:
11380444
47.
48.
49.

Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry.

Haya S, López MF, Aznar JA, Batlle J; Spanish Immune Tolerance Group.

Haemophilia. 2001 Mar;7(2):154-9.

PMID:
11260274
50.

A comparison of FVII:C and FVIIa assays for the monitoring of recombinant factor VIIa treatment.

Cid AR, Lorenzo JI, Haya S, Montoro JM, Casaña P, Aznar JA.

Haemophilia. 2001 Jan;7(1):39-41.

PMID:
11136379

Supplemental Content

Loading ...
Support Center